Mengye He

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

Myeloid-derived suppressor cells coming of age

The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Myeloid‐derived suppressor cell heterogeneity in human cancers

The Tumor Microenvironment Innately Modulates Cancer Progression

Increased circulating Lin^−/lowCD33⁺HLA‐DR⁻ myeloid‐derived suppressor cells in hepatocellular carcinoma patients